At the core of this initiative lies the lead compound, SBI-810, a second-generation drug candidate derived from meticulous medicinal chemistry optimization, reinforced by receptor signaling analyses and efficacy testing. These efforts leverage state-of-the-art cryo-electron microscopy structural insights alongside artificial intelligence algorithms, creating a feedback loop of molecular refinement intended to maximize therapeutic efficacy while enhancing safety profiles. This iterative approach exemplifies a sophisticated leap forward in drug design, promising a new class of pain therapeutics that avoid the pitfalls of addiction and severe side effects characteristic of opioid analgesics.

The pressing need for such innovation arises from staggering clinical statistics: each year, nearly 80% of 19 million Americans undergoing major surgeries endure postoperative pain, while over 25 million individuals suffer chronic pain worldwide. Despite the prevalence, current analgesic regimens are often insufficient or fraught with complications, notably opioid-based treatments which carry profound risks such as dependence, overdose, and myriad side effects. SBI-810 targets this unmet medical need by engaging neurotensin receptor 1 (NTR1), a G protein-coupled receptor implicated in pain signaling pathways, yet does so via an unprecedented molecular mechanism.

Unlike traditional receptor agonists that bind centrally to active sites, SBI-810 acts as a biased allosteric modulator (BAM) by attaching to a cryptic intracellular pocket within NTR1. This mode of binding selectively promotes β-arrestin-2 pathway activation while suppressing G-protein mediated signaling linked to pain propagation and deleterious physiological responses. The selective modulation offers potent analgesia without inducing hypotension or hypothermia, adverse effects that historically limited the clinical advancement of NTR1-targeting compounds. This molecular precision heralds a paradigm shift in receptor pharmacology, focusing on signal bias to uncouple therapeutic effects from side effects.

The foundational science underpinning SBI-810 builds on seminal work revealing the potent analgesic properties of neurotensin, the natural ligand for NTR1. Decades ago, neurotensin was found to surpass morphine in antinociceptive potency; however, its clinical utility was hindered by systemic side effects. Dr. Ru-Rong Ji articulates this challenge: harnessing neurotensin’s analgesic power safely required novel strategies. Using structural biology and drug design, the research team has designed compounds that selectively funnel receptor signaling into beneficial routes, overcoming this historical barrier.

Recent high-impact publications underpin the grant’s rationale. A 2025 study in Cell unveiled the multifaceted efficacy of SBI-810 across diverse rodent pain models, including postoperative, inflammatory, and neuropathic conditions. Notably, the compound modulated pain signaling in human sensory neurons, an essential translational milestone. Crucially, SBI-810 reduced opioid-induced side effects, which may enable combination therapies that enhance analgesia while mitigating opioid-related harm. Complementing this, another 2025 Nature publication elucidated the molecular architecture governing biased signaling by the parent molecule SBI-553, revealing how intracellular binding pockets redirect receptor-protein interactions. These insights lay the structural groundwork for precision drug design within the largest receptor family: G protein-coupled receptors (GPCRs).

GPCRs constitute the most extensive and versatile family of membrane receptors, orchestrating cellular responses to extracellular signals such as neurotransmitters, hormones, and environmental stimuli. Their ubiquitous role in physiology renders GPCRs prime pharmacological targets, with approximately one-third of all marketed drugs acting on these receptors. This new class of biased allosteric modulators introduces a transformative approach to modulating GPCR function, emphasizing specificity in downstream signaling cascades rather than wholesale receptor activation.

Dr. Lauren M. Slosky emphasizes the transformative potential of integrating detailed structural understanding with computational methodologies. This fusion facilitates rational drug design by predicting how structural changes in compounds translate to altered receptor behavior and clinical outcomes. Such an approach mitigates the inefficiencies and uncertainties inherent in traditional empirical drug discovery, increasing the probability of clinical success.

The grant’s structure is designed to expedite the transition from laboratory discovery to clinical application through a phased strategy. The initial two-year phase concentrates on refining lead molecules by optimizing efficacy and eliminating cardiac safety liabilities detected in preliminary evaluations. Preclinical validation will employ well-established rodent pain models, with careful incorporation of sex as a biological variable to ensure broad therapeutic applicability. Subsequent phases hinge on success milestones, culminating in Investigational New Drug (IND) applications and phase 1 human safety and pharmacokinetic trials.

Underlying this endeavor is a multidisciplinary consortium that synergizes medicinal chemistry, GPCR structural biology, neurobiology, and translational pharmacology. Besides Olson, Ji, and Slosky, the team includes notable scientists such as Lawrence S. Barak, PhD, William C. Wetsel, PhD, Changlu Liu, PhD, and Michael R. Jackson, PhD. This collaborative framework exemplifies the NIH HEAL Initiative’s mission to harness interdisciplinary expertise to combat opioid addiction and chronic pain through innovative therapeutics.

Steven H. Olson reflects on the broader implications of this work, highlighting the grant’s enabling role in transforming a promising preclinical molecule into a potential new medicine. The integration of chemistry, structural biology, and rigorous in vivo pharmacology across multiple institutions provides a robust platform to tackle one of medicine’s most daunting challenges: effective, non-addictive pain relief. This initiative not only aims to alleviate suffering for millions worldwide but also to set a blueprint for future GPCR-targeted drug discovery efforts.

The NIH HEAL Initiative, which funds this research, launched in 2018 with the goal of accelerating solutions to the opioid crisis, spanning prevention, treatment of addiction, and improved pain management strategies. By fostering bold, collaborative science projects such as this one, HEAL is catalyzing the development of innovative drugs designed to diminish reliance on opioids while addressing chronic and acute pain safely and effectively.

Sanford Burnham Prebys Medical Discovery Institute, now celebrating its 50th anniversary, continues to be at the forefront of biomedical research focused on fundamental human biology and translational science. The institute’s strength lies in its integrated centers of excellence across cancer, neuroscience, cardiovascular, metabolic, and liver diseases, complemented by cutting-edge capabilities in data science, artificial intelligence, and drug discovery. This environment fuels transformative discoveries with the potential to revolutionize health care globally.

Subject of Research: Development of a non-opioid pain therapeutic targeting neurotensin receptor 1 using biased allosteric modulation and structure-guided drug design.

Article Title: NIH HEAL Initiative Funds $3.9 Million to Propel Non-Addictive Pain Therapeutic Toward Clinical Trials

News Publication Date: 2025

Web References:
– NIH HEAL Initiative: https://heal.nih.gov/
– Cell Publication on SBI-810: https://www.cell.com/cell/abstract/S0092-8674(25)00508-2
– Nature Publication on SBI-553: https://www.nature.com/articles/s41586-025-09643-2

References: Research supported by NIH/NINDS Award Number UG3NS141745.

Image Credits: Sanford Burnham Prebys Medical Discovery Institute.

Keywords: Non-opioid pain treatment, neurotensin receptor 1, biased allosteric modulator, SBI-810, GPCR drug discovery, cryo-electron microscopy, artificial intelligence, medicinal chemistry, opioid epidemic, translational pharmacology, NIH HEAL Initiative, chronic pain.

Traditional methodologies for generating antibodies usually involve immunizing animals, a process that often leads to incomplete or unsuccessful outcomes when it comes to antibodies related to protein complexes. The underlying challenge lies in the inherent instability of these complexes during the immunization phase, which significantly disrupts the immune response. This impediment ultimately hampers the generation of effective antibodies capable of binding to biological entities involved in critical physiological pathways.

A groundbreaking study, jointly conducted by esteemed scientists at Sanford Burnham Prebys and Eli Lilly and Company, addresses this long-standing issue. The research, published on March 5, 2025, in the Journal of Immunology, has unveiled a novel technique that enhances the stability of protein complexes through fusion methods. By fusing these complexes, researchers have not only improved their stability but also enabled the effective generation of monoclonal antibodies targeted towards them.

The focal point of this innovative study was the interaction between two pivotal proteins present on immune cells: B and T lymphocyte attenuator (BTLA) and herpesvirus entry mediator (HVEM). These proteins are known to engage in a significant complex to modulate immune response intensity. Through meticulous experimentation, scientists demonstrated that the ratios of the independent forms of these proteins to their fused counterparts are crucial for understanding disease mechanisms, particularly in autoimmune diseases such as lupus, where measurement challenges have historically complicated research efforts.

As part of their investigatory approach, the researchers synthesized a fusion protein comprising the BTLA-HVEM complex. This strategic fusion not only provided necessary stability during immunization processes but also enabled the successful generation of specific monoclonal antibodies. Such antibodies were critical in distinguishing between unbound BTLA and HVEM proteins and their complex forms across various immune cell populations. This aspect of the study marks a significant milestone in the field, showcasing for the first time the direct measurement capabilities of these complexes in living cells using complex-specific monoclonal antibodies.

Leading this pioneering research, Dr. Carl Ware, a prominent professor in the Cancer Metabolism and Microenvironment Program at Sanford Burnham Prebys, emphasized the implications of their findings for clinical diagnostics. He noted that these methodologies could enhance diagnostic protocols for lupus and certain lymphoma types, especially those linked with mutations in the HVEM gene. He pointed to the pressing need for reliable biomarkers in these conditions, where current diagnostic tools often fall short.

Moreover, the study reiterates the potential of this novel antibody-generation approach using fusion proteins. Dr. Ware passionately advocated that this method could serve as a gateway for future investigations into other critical protein complexes associated with various diseases. Such advancements might not only uncover underlying pathophysiological mechanisms but could also lead to innovative therapeutic strategies that offer greater efficacy and specificity.

The contribution of Dr. Shane Atwell, senior director of biologics research at Neurocrine Biosciences, who worked at Eli Lilly during the study, is highlighted as he shares lead authorship with Dr. Tim Cheung, an associate professor based in Dr. Ware’s laboratory. This collaborative work signifies not only an interdisciplinary approach but also underscores how partnerships between academia and industry can catalyze breakthroughs in medical science.

Additional authors who contributed to this study include researchers from both Sanford Burnham Prebys and Eli Lilly, collectively enriching the investigative framework. This collaborative effort mirrors the essence of modern scientific inquiry, where shared expertise is paramount to tackling complex biological challenges.

The financial backing for the study was made possible through the SBP-Lilly Collaborative Research Agreement, which demonstrates the importance of support in translating research from concept to practical applications. Such funding is essential for fostering innovation and encouraging researchers to pursue novel avenues that push the boundaries of current scientific knowledge.

The implications of this research extend beyond the immediate findings, as they lay the groundwork for future exploration in related fields such as cancer immunotherapy and autoimmune disease management. The fusion protein strategy could not only revolutionize how antibodies are generated for studying intricate protein interactions but may also influence the design of vaccines and other therapeutic agents.

The commitment to advancing scientific understanding through innovative research methodologies such as those demonstrated in this study epitomizes the fundamental goal of the biomedical community. This study not only contributes valuable knowledge to the field but also inspires further inquiry into the complexities of immune system interactions, encouraging generations of future scientists to continue the pursuit of effective therapies for challenging medical conditions.

In summary, this groundbreaking study sheds light on a compelling strategy for overcoming hurdles in antibody generation. By employing fusion proteins to stabilize protein complexes, researchers have unlocked new possibilities for targeted therapies and diagnostic tools in immunology and beyond, reflecting the ever-evolving landscape of biomedical research and its potential impact on patient care.

Subject of Research: Animals
Article Title: Quantitative detection of the HVEM-BTLA checkpoint receptor cis-complex in human lymphocytes
News Publication Date: 5-Mar-2025
Web References: Journal of Immunology
References: DOI: 10.1093/jimmun/vkae057
Image Credits: Credit: Sanford Burnham Prebys

Keywords: Monoclonal antibodies, Antibody therapy, Protein complexes, Chimeric proteins, Animal research, Clinical research, Vaccine research, Immunization, Immune response, Drug research.

Among the various forms of CK, a particular type known as ubiquitous mitochondrial creatine kinase (uMtCK) has drawn considerable attention, particularly in the context of breast cancer research. The uMtCK operates as a linchpin in energy management within these malignant cells, effectively coordinating the transfer of ATP—adenosine triphosphate, the primary energy currency of cells. By hijacking the biochemical pathways governed by these kinases, cancer cells can maintain their high energy demands, enabling rapid cell division and survival in hostile environments.

In their groundbreaking study published in the journal Structure, researchers reported the first detailed structural insights into human uMtCK and how its form changes upon binding with creatine and adenosine triphosphate (ATP). Utilizing advanced cryogenic electron microscopy (cryo-EM), the team was able to obtain high-resolution three-dimensional images of uMtCK. This technology, which captures the position of individual atoms, provides invaluable blueprints that can inform future drug development aimed at curbing the energy-capturing capabilities of cancer cells.

The structural data obtained from this study elucidates not only the binding dynamics of uMtCK with its substrates but also its interplay with other proteins pivotal for transporting energy throughout cells. This enhanced understanding is critical, as it opens new avenues for therapeutic intervention. The research underscores the potential for designing targeted treatments that could inhibit uMtCK’s function specifically, thereby disrupting the energy supply chain of breast cancer cells without broadly tampering with other important cellular processes.

An important aspect of the study also involved the examination of CKi, the only existing CK inhibitor currently available, which the researchers evaluated for its potential efficacy in treating breast cancer. Their findings demonstrated that CKi could effectively diminish the growth of breast cancer cells. Yet caution is warranted; the study notes that CKi lacks selectivity for uMtCK, leading to the likelihood that this inhibitor may disrupt additional essential cellular functions even beyond the energy pathways associated with cancer, potentially resulting in considerable toxicity to normal cells.

The implications of this research are profound. With the foundation laid by this structural analysis, the researchers aim to collaborate further to develop novel small molecules. These new compounds would ideally be designed to selectively inhibit uMtCK, providing a more targeted therapeutic strategy. As every scientist knows, the balance between efficacy and safety is paramount in drug design—a lesson that this research clearly emphasizes.

This study’s authors have collectively contributed to the ongoing effort of understanding cancer’s metabolic dependencies. Merve Demir, as the lead author, alongside senior author Eduard Sergienko, highlights the importance of collaborative research in unraveling the complexities of cancer biology. Their findings are underpinned and supported by significant grants from reputable institutions, including the National Institutes of Health and the National Cancer Institute, signaling the high stakes involved in cancer research and the urgency for new treatment modalities.

Additionally, the findings present a wealth of data that could impact broader fields beyond cancer treatment, including metabolic disorders, where energy transport pathways are equally critical. Exploring the role of uMtCK in these diseases could reveal new dimensions and therapeutic approaches that may benefit a wider array of patients.

Given the monumental impact of energy metabolism on cancer progression, researchers are now driven to further investigate the specific pathways and molecular interactions involving uMtCK. Each piece of research contributes to constructing a comprehensive map of cellular metabolism, providing the clues needed to confront cancer par excellence. Understanding these mechanistic details at the molecular level may prove to be the key to unlocking breakthroughs in how we treat various cancers and how we can create therapies that target their unique vulnerabilities.

The anticipated future research surrounding uMtCK and its inhibitors is likely to pave the way for innovative strategies to combat not just breast cancer, but potentially numerous other types that similarly exploit cellular energy pathways. As advancements in biotechnology and structural biology continue to emerge, the hope is that the findings will translate into viable therapeutic options, drastically changing the prognosis for cancer patients globally.

In conclusion, the fight against cancer is poised to make significant strides thanks to revelations from current research, such as that from the Mayo Clinic and Sanford Burnham Prebys. With every study, scientists inch closer towards understanding the intricate dance of life at the molecular level, unlocking the door to a future where cancer might no longer be an inexorable foe but rather a manageable condition.

Subject of Research: Cells
Article Title: Structural basis for substrate binding, catalysis and inhibition of cancer target mitochondrial creatine kinase by a covalent inhibitor
News Publication Date: 3-Feb-2025
Web References: DOI: 10.1016/j.str.2025.01.008
References: National Institutes of Health, National Cancer Institute, Conrad Prebys Foundation
Image Credits: Credit: Sanford Burnham Prebys

Keywords

Life sciences, Biochemistry, Pharmacology, Drug development, Drug design, Energy resources, Cellular energy, Kinases, Breast cancer cells, Kinase inhibitors, Small molecule inhibitors, Atomic structure, Protein structure, Mitochondrial function, Cancer research.